CHE

Chemed Corporation (CHEM) - Q1 2026 Filing Summary

Business Context and Reporting Period

This summary covers the Unaudited Consolidated Financial Statements for Chemed Corporation for the quarterly period ended March 31, 2026. Chemed operates through two primary segments: VITAS Healthcare (hospice care) and Roto-Rooter (plumbing, drain cleaning, and water restoration). The company is a large accelerated filer incorporated in Delaware.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Consolidated revenue increased 1.6% year-over-year. This was driven by a 3.1% increase in VITAS revenue (due to a 2.2% increase in days-of-care and a 2.6% Medicare reimbursement rate increase) offset by a 0.9% decline in Roto-Rooter revenue (driven by decreases in commercial and residential volumes).
• Profitability: Net income decreased 7.6% to $66.3 million. VITAS net income rose to $52.2 million, while Roto-Rooter net income fell to $35.8 million due to increased marketing expenses. Corporate expenses increased 19.1% due to higher intercompany interest and lower tax benefits.
• Liquidity and Debt: Cash and cash equivalents dropped significantly by $57.7 million to $16.9 million, primarily due to $190.0 million in share repurchases and $20.6 million in acquisition costs. Long-term debt increased by $91.2 million, funded by a revolving line of credit to support acquisitions and buybacks.
• Balance Sheet: Accounts receivable increased by $32.9 million, largely due to the timing of federal government payments for VITAS. Goodwill increased by $20.5 million following two Roto-Rooter franchise acquisitions.

Guidance, Outlook, and Risks

• Outlook: Management does not expect a material negative effect on net sales or profitability for the remainder of fiscal year 2026 from recently implemented tariffs or the war with Iran, though they are evaluating potential cost increases for 2027 planning.
• Capital Allocation: The Board authorized an additional $300.0 million for stock repurchases in February 2026. As of March 31, 2026, $229.6 million remained available under the program. The company also replaced its credit facility with a new $450.0 million revolving credit agreement.
• Risks and Contingencies:
  • Regulatory: VITAS remains subject to Medicare/Medicaid audits. A significant audit regarding elevated level-of-care services was resolved favorably in early 2025, resulting in a refund of previously deposited funds.
  • Legal: Class action lawsuits regarding a cybersecurity incident in October 2025 have been settled for a non-material amount covered by insurance.
  • Concentration: Approximately 81% of consolidated net accounts receivable are due from Medicare, Medicaid, and managed Medicaid programs.

Investor Verification Checklist

• Cash Position: Verify the sustainability of operations with cash reserves at $16.9 million, given the heavy reliance on the revolving credit facility ($91.2 million drawn) for liquidity.
• Share Repurchases: Confirm the impact of $190 million in buybacks on future capital flexibility and the remaining $229.6 million authorization.
• VITAS Revenue Mix: Monitor the "Acuity mix shift" which negatively impacted revenue growth by 120 basis points, and the continued effect of the Medicare Cap adjustment.
• Roto-Rooter Margins: Review the decline in water restoration revenue (-11.7%) and the impact of increased advertising spend on segment profitability.
• Debt Covenants: Ensure continued compliance with the new Credit Agreement covenants (Leverage Ratio < 3.50x; Interest Coverage > 3.00x).